Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05886920 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
A Phase 1 study of Advanced Solid Tumors With MAPK Pathway Mutations, sponsored by D3 Bio (Wuxi) Co..
- Active
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
- 10
- Study locations
NCT05886920 is a Phase 1 study of Advanced Solid Tumors With MAPK Pathway Mutations that is active but no longer recruiting, run by D3 Bio (Wuxi) Co.. The registered enrollment target is 67 participants. The trial reports 10 study locations across 10 states.
The verdict
NCT05886920, a Phase 1 study of Advanced Solid Tumors With MAPK Pathway Mutations, is active but no longer recruiting, sponsored by D3 Bio (Wuxi) Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
- 10
- Study locations
Study Summary
This first-in-human (FIH) study aims to assess the safety, tolerability, pharmacokinetics, and recommended phase 2 dose (RP2D) of D3S-002 given orally daily for 21-day cycles in adult subjects with advanced solid tumors with mitogen-activated protein kinase (MAPK) pathway mutations.
Conditions Studied
Interventions
- DRUG D3S-001
- DRUG D3S-002
Study Locations (10)
Michigan
- D3 Bio Investigative Site - Detroit
New York
- D3 Bio Investigative Site - New York
New South Wales
- D3 Bio Investigative Site - Blacktown
South Australia
- D3 Bio Investigative Site - Bedford Park
Western Australia
- D3 Bio Investigative Site - Nedlands
Beijing Municipality
- D3 Bio Investigative Site - Beijing
Guangdong
- D3 Bio Investigative Site - Guangzhou
Heilong Jiang
- D3 Bio Investigative Site - Harbin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2023-07-10 |
| Est. Completion | 2028-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05886920
The ClinicalTrials.gov registry entry for NCT05886920 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is D3 Bio (Wuxi) Co., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors With MAPK Pathway Mutations appearing as the primary indexed condition, and to 2 interventions - of which D3S-001 is the first listed.
NCT05886920 reports 10 study locations spanning 10 distinct geographic areas - top geographies include Michigan, New York, New South Wales.
Frequently Asked Questions
What is clinical trial NCT05886920 about?
NCT05886920 is a clinical study titled "A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations". This first-in-human (FIH) study aims to assess the safety, tolerability, pharmacokinetics, and recommended phase 2 dose (RP2D) of D3S-002 given orally daily for 21-day cycles in adult subjects with advanced solid tumors with mitogen-activated protein kinase (MAPK) pathway mutations.
What is the current status of trial NCT05886920?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2023-07-10. Estimated completion is 2028-04.
What conditions does trial NCT05886920 study?
This clinical trial studies the following conditions: Advanced Solid Tumors With MAPK Pathway Mutations.
What interventions are being tested in trial NCT05886920?
The interventions under investigation include: D3S-001 (DRUG), D3S-002 (DRUG).
Who is sponsoring clinical trial NCT05886920?
This trial is sponsored by D3 Bio (Wuxi) Co., which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05886920 being conducted?
This trial has 10 study locations across Michigan, New York, New South Wales, South Australia, Western Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.